Literature DB >> 16805873

Vagus nerve stimulation inhibits activation of coagulation and fibrinolysis during endotoxemia in rats.

D J van Westerloo1, I A J Giebelen, J C M Meijers, J Daalhuisen, A F de Vos, M Levi, T van der Poll.   

Abstract

BACKGROUND: Sepsis and endotoxemia are associated with concurrent activation of inflammation and the hemostatic mechanism, which both contribute to organ dysfunction and death. Electrical vagus nerve stimulation (VNS) has been found to inhibit tumor necrosis factor (TNF)-alpha release during endotoxemia in rodents.
OBJECTIVE: To determine the effect of VNS on activation of coagulation and fibrinolysis.
METHODS: Rats received a sublethal i.v. dose of lipopolysaccharide (LPS) after electrical VNS or sham stimulation. Activation of coagulation and fibrinolysis, as well as cytokine release, was measured before LPS injection and 2, 4 and 6 h thereafter.
RESULTS: LPS induced activation of the coagulation system (increases in the plasma concentrations of thrombin-antithrombin complexes and D-dimer, and a decrease in antithrombin) and biphasic changes in the fibrinolytic system [early rises of plasminogen activator activity and tissue-type plasminogen activator, followed by a delayed increase in plasminogen activator inhibitor type 1 (PAI-1)]. VNS strongly inhibited all LPS-induced procoagulant responses and more modestly attenuated the fibrinolytic response. In addition, VNS attenuated the LPS-induced increases in plasma and splenic concentrations of the proinflammatory cytokines TNF-alpha and interleukin-6 (IL-6), while not influencing the release of the anti-inflammatory cytokine IL-10.
CONCLUSION: These data illustrate a thus far unrecognized effect of VNS and suggest that the cholinergic anti-inflammatory pathway not only impacts on inflammation but also on the coagulant-anticoagulant balance.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16805873     DOI: 10.1111/j.1538-7836.2006.02112.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  27 in total

Review 1.  Nicotinic acetylcholine receptor α7 subunit: a novel therapeutic target for cardiovascular diseases.

Authors:  Chong Liu; Dingfeng Su
Journal:  Front Med       Date:  2012-03-31       Impact factor: 4.592

2.  Electrical vagus nerve stimulation and nicotine effects in peritonitis-induced acute lung injury in rats.

Authors:  Claire Boland; Valérie Collet; Emmanuelle Laterre; Corinne Lecuivre; Xavier Wittebole; Pierre-François Laterre
Journal:  Inflammation       Date:  2011-02       Impact factor: 4.092

Review 3.  Physiology and immunology of the cholinergic antiinflammatory pathway.

Authors:  Kevin J Tracey
Journal:  J Clin Invest       Date:  2007-02       Impact factor: 14.808

4.  Heart rate and microinflammation in men: a relevant atherothrombotic link.

Authors:  O Rogowski; I Shapira; A Shirom; S Melamed; S Toker; S Berliner
Journal:  Heart       Date:  2007-01-19       Impact factor: 5.994

Review 5.  Cholinergic control of inflammation.

Authors:  M Rosas-Ballina; K J Tracey
Journal:  J Intern Med       Date:  2009-06       Impact factor: 8.989

6.  Effects of afferent and efferent denervation of vagal nerve on endotoxin-induced oxidative stress in rats.

Authors:  Omar M E Abdel-Salam; Rehab Fawzy Abdel-Rahman; Amany A Sleem; Fatma Adly Mosry; Hafiza A Sharaf
Journal:  J Neural Transm (Vienna)       Date:  2013-06-23       Impact factor: 3.575

7.  Nicotine exposure alters in vivo human responses to endotoxin.

Authors:  X Wittebole; S Hahm; S M Coyle; A Kumar; S E Calvano; S F Lowry
Journal:  Clin Exp Immunol       Date:  2007-01       Impact factor: 4.330

Review 8.  Targeting the "cytokine storm" for therapeutic benefit.

Authors:  Riccardo V D'Elia; Kate Harrison; Petra C Oyston; Roman A Lukaszewski; Graeme C Clark
Journal:  Clin Vaccine Immunol       Date:  2013-01-02

9.  NDP-MSH inhibits neutrophil migration through nicotinic and adrenergic receptors in experimental peritonitis.

Authors:  Jozi Figueiredo; Ana Elisa Ferreira; Rangel Leal Silva; Luis Ulloa; Paolo Grieco; Thiago Mattar Cunha; Sérgio Henrique Ferreira; Fernando de Queiróz Cunha; Alexandre Kanashiro
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2013-01-22       Impact factor: 3.000

10.  Dexmedetomidine controls systemic cytokine levels through the cholinergic anti-inflammatory pathway.

Authors:  Hui Xiang; Bo Hu; Zhifeng Li; Jianguo Li
Journal:  Inflammation       Date:  2014-10       Impact factor: 4.092

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.